UBS Group’s Centessa Pharmaceuticals CNTA Stock Holding History

UBS Group’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,300	Closed	-$883K	–	10584
2025 Q4	$883K	Sell	35,300 -10,000	-22%	-$253K	﹤0.01%	5684
2025 Q3	$1.1M	Hold	45,300	–	–	﹤0.01%	5494
2025 Q2	$595K	Buy	+45,300	New	+$574K	﹤0.01%	5866

UBS Group's CNTA Position: Q2 2026 in Review

UBS Group sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 359,939 shares — an estimated $14.3M sold.

UBS Group first reported a position in CNTA in Q2 2021 and held it in 18 quarters. The position peaked at $17.9M in Q4 2024. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

UBS Group reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
UBS Group sold 359,939 Centessa Pharmaceuticals shares in Q2 2026, an estimated $14.3M.
UBS Group first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 18 quarters.
UBS Group's Centessa Pharmaceuticals position peaked at $17.9M in Q4 2024.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.